Your SlideShare is downloading. ×
  • Like
  • Save
Micheal Caulfield
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply
Published

The Challenges of Developing New Markets for a Start-Up - Technology, Trials, Standards and Ethics.

The Challenges of Developing New Markets for a Start-Up - Technology, Trials, Standards and Ethics.

Published in Health & Medicine
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
946
On SlideShare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide
  • WHAT IS THE HEALTHCARE CHALLENGE?
  • Who are your competitors? How strong are they? Are they well funded? How many are there? What are the relative strengths against your solution? It may useful to show a competitor matrix showing how benefits/features of your product/technology compares
  • TO SUMMARISE

Transcript

  • 1. The challenges facing a medtech start-up in developing new markets – technology, standards, trials and reimbursement Michael Caulfield – CEO Intelesens Ltd
  • 2.
    • Patents in
    • Electrode chemistry, physics and electrophysiology 2001
    • Pulse Wave Velocity 2001
    • Breath Gas Detection ppb 2001
    • Biometric algorithm 2008
    • Blood oxygenation 2008
    • Electrode topology 2007
    • Electromechanical fastening 2008
    • Monitoring system 2002
    • ECG accelerometer 2009
    • Non-patented IP
    • ECG arrhythmia detection and identification algorithms
  • 3.  
  • 4. welcomes The world’s first intelligent, wearable, non-invasive, wireless device monitoring the patient’s vital signs remotely www.intelesens.com
  • 5.
    • 300 million people in Europe and the US have at least one chronic disease that may benefit from home health monitoring.
    • US and Europe market size for home health monitoring of chronic diseases > $11 billion last year
    • Problem is growing at 10 percent per year
    • 25 percent of that population would benefit from existing home monitoring solutions currently available, while some 50 percent would benefit from integrating or connecting existing medical devices with their mobile phones.
    • - Berg Insight
    EU and US The Market
  • 6. Our focus is on improving the quality of care for aging and ill populations while delivering compelling cost advantages and benefits for healthcare providers Our value proposition
  • 7. Our Products
  • 8. Vitalsens V-Patch wireless monitor measuring 3-lead ecg, heart rate, and detecting cardiac arrhythmias regulatory approval 2009 regulatory approval 2011
  • 9. Vitalsens V-Patch wireless monitor measuring 3-lead ecg, heart rate, and detecting cardiac arrhythmias
  • 10. Vitalsens Aingeal in-hospital wi-fi monitor measuring ecg, heart rate, respiration rate, temperature and motion in an ambulatory patient regulatory approval 2011 regulatory approval 2010
  • 11. The Competition
  • 12. The Trials
  • 13. Vitalsens March 2010 Trial 1
  • 14. Aingeal General Purpose In-Hospital Monitor - July 2010 A clinical trial using the Aingeal monitor began in Massachusetts General Hospital in Boston in July 2010 The Aingeal device will be used in a surgical ward and will measure ecg, heart rate, respiration rate, temperature and motion. It communicates with patient records database via the hospital’s wi-fi network Trial 2
  • 15. Trial 3 AMNCH Hospital Dublin V-Patch used to monitor cardiac patients at home http:// canberra.intelesens.com /Demo/
  • 16. Technology Phase Trials and Testing Phase Adoption, Reimbursement and Procurement Phase Marketing and Sales Phase Ulster MGH Tallaght
  • 17.  
  • 18. In-hospital, wireless vital signs monitor At-home, wireless vital signs monitor temp resp pulse ox ecg motion Delays and avoids ward admissions Expedites hospital discharge ecg SpO 2 temp resp motion